Amgen Submits Supplemental Biologics License Application For BLINCYTO ® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval Additional Data Support Treatment of Patients With Philadelphia Chromosome-Positive Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia BLINCYTO is the First Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Antibody and First Immunotherapy to Demonstrate Overall Survival Benefit Versus Standard of Care Chemotherapy THOUSAND OAKS, Calif., Feb. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for BL...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news